Prelude therapeutics reports second quarter 2025 financial results and provides corporate update

Prt7732, once daily oral smarca2 degrader, currently enrolling at the seventh dosing cohort (125 mg); company to provide an update with preliminary clinical data, including pk/pd, safety and initial clinical activity by year end 2025 phase 1 study of prt3789, a once weekly iv smarca2 degrader, has been completed; company to provide final data by year end 2025 prelude is advancing a development candidate for its oral kat6a degrader program and remains on track to file an ind in the first half of 2026 current cash runway into the second quarter of 2026 with $77.3 million in cash, cash equivalents, restricted cash and marketable securities as of june 30, 2025  wilmington, del., aug. 14, 2025 (globe newswire) -- prelude therapeutics incorporated (nasdaq: prld), a clinical-stage precision oncology company, today reported its financial results for second quarter ended june 30, 2025, and provided an update on its clinical development pipeline and other corporate developments.
PRLD Ratings Summary
PRLD Quant Ranking